Skip navigation |
Home
[Viewing options]

January

Management of Depression During Hepatitis C Treatment with Interferon-based Therapy
Management of Depression During Hepatitis C Treatment with Interferon-based Therapy
 
Egypt - Hope against hepatitis C
Egypt - Hope against hepatitis C
 
HIV/HCV Coinfected Patients with Persistently Normal ALT Can Develop Advanced Fibrosis, but Respond Better to Interferon based Therapy
HIV/HCV Coinfected Patients with Persistently Normal ALT Can Develop Advanced Fibrosis, but Respond Better to Interferon based Therapy
 
People Re-infected with Hepatitis C Are More Likely to Spontaneously Clear Virus, Indicating Partial Immunity
People Re-infected with Hepatitis C Are More Likely to Spontaneously Clear Virus, Indicating Partial Immunity
 
Pharmacy testing pilot diagnoses 1 in 6 clients with hepatitis B or C
Pharmacy testing pilot diagnoses 1 in 6 clients with hepatitis B or C
 
Quercetin Appears to Block Hepatitis C Virus Production
Quercetin Appears to Block Hepatitis C Virus Production
 
Liver Donations From Living Donors Increase 42% After Educational Intervention
Liver Donations From Living Donors Increase 42% After Educational Intervention
 
Sleep Disorders in People with Hepatitis C
Sleep Disorders in People with Hepatitis C
 
Hepatitis C group launches to aid thousands of Edinburgh patients
Hepatitis C group launches to aid thousands of Edinburgh patients
 
Low-dose Pegylated Interferon Maintenance Therapy Does Not Reduce Clinical Outcomes despite Persistent HCV Suppression
Low-dose Pegylated Interferon Maintenance Therapy Does Not Reduce Clinical Outcomes despite Persistent HCV Suppression
 
Management of Non-responders and Relapsers Treated with Pegylated Interferon plus Ribavirin for Chronic Hepatitis C
Management of Non-responders and Relapsers Treated with Pegylated Interferon plus Ribavirin for Chronic Hepatitis C
 
Natural compound blocks hepatitis C infection
Natural compound blocks hepatitis C infection
 
Post-Transplant Liver Stiffness May Predict Fibrosis Risk
Post-Transplant Liver Stiffness May Predict Fibrosis Risk
 
A Liverpool doctor has been named as the Government’s first tsar for liver disease
A Liverpool doctor has been named as the Government’s first tsar for liver disease
 
Department Of Health Appoints First National Clinical Director for Liver Disease
Department Of Health Appoints First National Clinical Director for Liver Disease
 
New research finds promising treatment for hepatitis C
New research finds promising treatment for hepatitis C
 
New tests for ‘silent killer’ urged
New tests for ‘silent killer’ urged
 
Pharmacy testing pilot diagnoses 1 in 6 clients with hepatitis B or C
Pharmacy testing pilot diagnoses 1 in 6 clients with hepatitis B or C
 
Randomized Study of Peginterferon-α2a Plus Ribavirin vs Peginterferon-α2b Plus Ribavirin in Chronic Hepatitis C
Randomized Study of Peginterferon-α2a Plus Ribavirin vs Peginterferon-α2b Plus Ribavirin in Chronic Hepatitis C
 
Real-World Treatment Patterns, Non-Adherence, And Costs In Chronic Hepatitis C
Real-World Treatment Patterns, Non-Adherence, And Costs In Chronic Hepatitis C
 
Engineering a new way to study hepatitis C
Engineering a new way to study hepatitis C
 
Viramidine Fails to Show Non-inferiority to Ribavirin at Tested Doses but Causes Less Anemia
Viramidine Fails to Show Non-inferiority to Ribavirin at Tested Doses but Causes Less Anemia
 
 
 
Helpline Association Info standard

The Hepatitis C Trust is a registered charity. We have adopted the Information Standard which means we are committed to providing reliable and evidence-based information.

Click here if you require further information on any page within this site.

Charity Registration Numbers: Scotland SC039914, England and Wales 1104279

©2012 Hepatitis C Trust
Built on Cubik